• Subscribe
  • Magazine
  • Videos
  • Advertise
  • About Us
  • Smart Water Summit
  • Wastewater Summit
    • Recent Quotes
    My Watchlist
    Indicators
    WaterWorld Market Index
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Cardiol Therapeutics Inc. - Class A Common Shares (NQ: CRDL )

    1.253 -0.027 (-2.14%)
    Streaming Delayed Price Updated: 11:27 AM EST, Dec 23, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 308,689
    Open 1.420
    Bid (Size) 1.250 (23)
    Ask (Size) 1.260 (3)
    Prev. Close 1.280
    Today's Range 1.233 - 1.420
    52wk Range 0.8110 - 3.120
    Shares Outstanding N/A
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    “Cardiol Therapeutics (NASDAQ: CRDL) Heart Health Innovation – AVCO, GXAI, UPC, and More Stocks Driving Groundbreaking Advances”
    Via AB Newswire
    3 Penny Stocks Ready to Break Out in 2025
    Vuzix, GeoVox Labs, and Cardiol Therapeutics emerged as notable penny stocks late in 2024 for their potential to scale operations and launch new products. 
    Via MarketBeat

    Performance

    YTD
    +42.34%
    +42.34%
    1 Month
    -22.68%
    -22.68%
    3 Month
    -45.54%
    -45.54%
    6 Month
    -37.37%
    -37.37%
    1 Year
    +50.23%
    +50.23%

    More News

    Read More
    Thanksgiving Week Oversold Stocks to Watch: CRDL, QBTS, PRSO, RGTI & More!
    Via AB Newswire
    “Game-Changers to Watch CRDL, RMSG, WORX, PET and more…Innovative Companies inside”
    Via AB Newswire
    Topics Economy
    Exposures Supply Chain
    Why Cardiol Therapeutics (CRDL) Stock Is Down 20% Today
    Via Benzinga
    Cardiol Therapeutics (Nasdaq: CRDL) Advances Orphan Drug Designation for CardiolRx™ at the American Heart Association…more stocks inside…
    Via AB Newswire
    CBD-Based Drug Reduces Pericarditis Pain And Inflammation, Shows New Clinical Study
    Via Benzinga
    Spotlight on Undervalued Nasdaq Stocks: HCWB, CRDL, NIVF, SINT, APLM – A Must-Watch This Week!
    Via AB Newswire
    Cardiol Therapeutics' Phase II MAvERIC-Pilot Clinical Results in Recurrent Pericarditis Presented at the American Heart Association Scientific Sessions 2024
    Via Newsfile
    “Emerging Innovators Transforming Global Markets: IPA, CRDL, KXIN, GNS, PRSO in Sectors”
    Via AB Newswire
    Topics Electric Vehicles
    Exposures Electric Vehicles Product Safety
    Biotech and Technology Giants Drive Innovation Across Pharma, Medical Devices, and Industrial Automation CRDL, MODD, CYN
    Via AB Newswire
    Exposures Product Safety
    “Trump Media (NASDAQ: DJT) Surges on Election Day as SmallCap Stocks CRDL, ALBT, ZVSA, PRSO Emerge”
    Via AB Newswire
    Topics Government
    Exposures Political
    “Top Biotech Opportunities: RVNC, HCTI, GLUE, PRSO, CRDL, Showing Promising Developments”
    Via AB Newswire
    Topics Artificial Intelligence
    Exposures Artificial Intelligence
    Healthcare and Biotech Stocks to Watch: MODD, CRDL, DBVT, VRAX
    Via AB Newswire
    Topics Intellectual Property
    Exposures Intellectual Property
    Cardiol Therapeutics’ (NASDAQ: CRDL) CardiolRx™ Addresses Urgent Medical Condition Myocarditis, a Leading Cause of Sudden Cardiac Death see more stocks inside…
    Via AB Newswire
    AZZ, Helen of Troy And 3 Stocks To Watch Heading Into Wednesday
    Via Benzinga
    “Cardiol Therapeutics (NASDAQ: CRDL) Myocarditis Breakthrough Featured on Fox Business: CardiolRx™ Poised for Medical Impact more stocks inside…”
    Via AB Newswire
    CRDL Stock Earnings: Cardiol Therapeutics Beats EPS for Q2 2024
    Via InvestorPlace
    Hope on the Horizon: Results from MAvERIC-Pilot Show Heartfelt Progress for Patients
    Via TheNewswire.com
    Exposures Product Safety
    Hope on the Horizon: Results from MAvERIC-Pilot Show Heartfelt Progress for Patients
    Via News Direct
    Exposures Product Safety
    Cardiol Therapeutics Announces Positive Topline Data from its Phase II MAvERIC-Pilot Study Investigating CardiolRx(TM) for Recurrent Pericarditis
    Via Newsfile
    Sector Spotlight: Orphan Drug Developers With Significant Upside
    Via AB Newswire
    Topics ETFs
    Exposures Product Safety
    Sector Spotlight: Orphan Drug Developers With Significant Upside
    Via TheNewswire.com
    Topics ETFs
    Exposures Product Safety
    Analysts Consensus Reaffirms Significant Upside Potential for Cardiol Therapeutics (NASDAQ:CRDL) (TSX:CRDL)
    Via AB Newswire
    Analysts’ Consensus Reaffirms Significant Upside Potential for Cardiol Therapeutics
    Via News Direct
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.